Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 55%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is positioned favorably, benefiting from the growing diagnosis of sleep apnea and an aging population, contributing to a structurally expanding market for its respiratory care devices. The company's strong financial performance is evidenced by a 12% year-over-year increase in revenue from masks and other products in the U.S., Canada, and Latin America, while also maintaining a strategy to return cash to shareholders through increased dividends and share repurchase initiatives. Furthermore, ResMed's commitment to invest in digital health solutions aims to enhance its market differentiation and support ongoing growth, indicating a solid outlook for revenue expansion alongside rising operating expenses.

Bears say

The analysis of ResMed indicates a negative outlook, primarily due to concerns about medium-term disruptions in Positive Airway Pressure (PAP) volumes attributed to the uptake of GLP-1 medications for treating obesity-related conditions. Furthermore, while ResMed is currently outpacing market growth, the potential impact of these medications on demand for masks and devices raises significant apprehension regarding future revenue streams. This situation is convoluted by ResMed's dependency on the Americas for approximately two-thirds of its revenue, making the company particularly vulnerable to shifts in healthcare trends related to sleep apnea treatment.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 55% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $297.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $297.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.